LSTA
LSTA
NASDAQ · Biotechnology

Lisata Therapeutics Inc

$1.50
-0.08 (-5.06%)
As of Sep 28, 10:32 PM ET ·
Financial Highlights (FY 2026)
Revenue
183.4K
Net Income
-17,863,989
Gross Margin
9.6%
Profit Margin
-9,756.5%
Rev Growth
-78.8%
D/E Ratio
—
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 9.6% 9.6% 60.2% 60.2%
Operating Margin -10,711.2% -9,640.1% -3.8% -3.7%
Profit Margin -9,756.5% -9,268.7% -3.8% -3.8%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 183.4K 866.6K 5.21M 4.72M
Gross Profit 17.5K 82.8K 3.14M 2.84M
Operating Income -19,642,483 -83,545,532 -199,396 -176,250
Net Income -17,863,989 -75,981,049 -195,079 -179,711
Gross Margin 9.6% 9.6% 60.2% 60.2%
Operating Margin -10,711.2% -9,640.1% -3.8% -3.7%
Profit Margin -9,756.5% -9,268.7% -3.8% -3.8%
Rev Growth -78.8% -78.8% -0.3% +24.4%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 0 0 21.25M 18.39M
Total Equity — — 13.67M 13.06M
D/E Ratio — — 1.55 1.41
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -19,454,561 -87,343,255 -244,954 -200,080
Free Cash Flow — — -167,798 -115,643